Related Experiment Video
Updated: Nov 24, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth via Targeting VEGFA
Xiaoyu Wang1, Yuanjian Fang1, Yunxiang Zhou2
1Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Background:
Nonfunctioning pituitary neuroendocrine tumor (NF-PitNET) is difficult to resect. Except for surgery, there is no effective treatment for NF-PitNET. MicroRNA-134 (miR-134) has been reported to inhibit proliferation and invasion ability of tumor cells. Herein, the mechanism underlying the effect of miR-134 on alleviating NF-PitNET tumor cells growth is explored.
Methods:
Mouse pituitary αT3-1 cells were transfected with miR-134 mimics and inhibitor, followed by treatment with stromal cell-derived factor-1α (SDF-1α) in vitro. MiR-134 expression level: we used quantitative real-time PCR (qRT-PCR) to detect the expression of miR-134. Cell behavior level: cell viability and invasion ability were assessed using a cell counting kit-8 (CCK8) assay and Transwell invasion assay respectively. Cytomolecular level: tumor cell proliferation was evaluated by Ki-67 staining; propidium iodide (PI) staining analyzed the effect of miR-134 on cell cycle arrest; western blot analysis and immunofluorescence staining evaluated tumor migration and invasive ability. Additionally, we collected 27 NF-PitNET tumor specimens and related clinical data. The specimens were subjected to qRT-PCR to obtain the relative miR-134 expression level of each specimen; linear regression analysis was used to analyze the miR-134 expression level in tumor specimens and the age of the NF-PitNET population, gender, tumor invasion, prognosis, and other indicators.
Results:
In vitro experiment, miR-134 was observed to significantly inhibit αT3-1 cells proliferation characterized by inhibited cell viability and expressions of vascular endothelial growth factor A (VEGFA) and cell cycle transition from G1 to S phase (P < 0.01). VEGFA was verified as a target of miR-134. Additionally, miR-134-induced inhibition of αT3-1 cell proliferation and invasion was attenuated by SDF-1α and VEGFA overexpression (P < 0.01). In primary NF-PitNET tumor analysis, miR-134 expression level was negatively correlated with tumor invasion (P = 0.003).
Conclusion:
The regulation of the SDF-1α/miR-134/VEGFA axis represents a novel mechanism in the pathogenesis of NF-PitNETs and may serve as a potential therapeutic target for the treatment of NF-PitNETs.
Insights
MicroRNA-134 (miR-134) inhibits nonfunctioning pituitary neuroendocrine tumor (NF-PitNET) growth by targeting VEGFA. This miR-134 pathway, regulated by SDF-1α, offers a potential therapeutic strategy for NF-PitNET.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Nonfunctioning pituitary neuroendocrine tumors (NF-PitNETs) lack effective treatments beyond surgery.
- MicroRNA-134 (miR-134) is a known inhibitor of tumor cell proliferation and invasion.
Purpose of the Study:
- To investigate the mechanism by which miR-134 affects NF-PitNET cell growth.
- To explore the potential of the miR-134 pathway as a therapeutic target for NF-PitNETs.
Main Methods:
- In vitro transfection of mouse pituitary αT3-1 cells with miR-134 mimics/inhibitor and SDF-1α treatment.
- Quantitative real-time PCR (qRT-PCR) for miR-134 expression.
- Cell viability (CCK8), invasion assays, Ki-67 staining, cell cycle analysis (PI staining), and Western blot/immunofluorescence for molecular evaluation.
- Analysis of 27 NF-PitNET specimens for miR-134 expression correlation with clinical parameters.
Main Results:
- miR-134 significantly inhibited αT3-1 cell proliferation, viability, and G1 to S phase transition.
- Vascular Endothelial Growth Factor A (VEGFA) was identified as a direct target of miR-134.
- SDF-1α and VEGFA overexpression attenuated miR-134's inhibitory effects on proliferation and invasion.
- Lower miR-134 expression correlated with increased tumor invasion in NF-PitNET specimens (P=0.003).
Conclusions:
- The SDF-1α/miR-134/VEGFA axis is a novel mechanism in NF-PitNET pathogenesis.
- This axis represents a potential therapeutic target for NF-PitNET treatment.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
MicroRNAs
MicroRNAs
Abnormal Proliferation

